📊 INBP Key Takeaways
Is Integrated Biopharma Inc. (INBP) a Good Investment?
INBP operates at significant losses with operating margin of -3.1% despite $24M revenue, indicating fundamental operational challenges. While the balance sheet is fortress-like with zero long-term debt and 5.03x current ratio, the extremely low 4.4% gross margin for a pharmaceutical company suggests severe pricing pressure, high production costs, or inefficient operations. Positive free cash flow masks underlying value destruction as the company burns equity capital.
Integrated BioPharma shows modest revenue growth and strong liquidity with no debt, while generating positive operating and free cash flow. However, extremely thin gross margins and ongoing operating losses indicate limited earnings power and sensitivity to cost/pricing pressures. Evidence of sustained margin expansion and consistent operating profitability would be needed to tilt positive.
Why Buy Integrated Biopharma Inc. Stock? INBP Key Strengths
- Zero long-term debt and no leverage provides financial flexibility
- Exceptional liquidity with 5.03x current ratio and 2.67x quick ratio enables short-term survival
- Positive free cash flow of $1.7M despite operating losses demonstrates working capital management
- Revenue growing 8% YoY showing modest top-line traction
- Cash reserves of $5.3M provide runway for operations and potential strategic pivots
- Debt-free balance sheet with strong liquidity (current ratio 5.03x; $5.31M cash)
- Positive operating and free cash flow with low capex needs
- Revenue growth (+8% YoY) and improved net loss trajectory
INBP Stock Risks: Integrated Biopharma Inc. Investment Risks
- Gross margin of 4.4% is critically low for pharmaceutical industry indicating structural profitability issues
- Operating losses of $751K on $24M revenue with negative operating margin of -3.1% show unsustainable business model
- Negative ROE (-3.2%) and ROA (-2.7%) indicate shareholder capital is being destroyed not created
- Net losses continuing despite revenue growth suggests cost structure is misaligned with business scale
- Minimal insider activity (3 Form 4 filings in 90 days) suggests low confidence from company leadership in near-term prospects
- Very thin 4.4% gross margin constrains profitability and resilience
- Negative operating income and ROE/ROA signal weak core earnings
- FCF may be boosted by working capital timing; small scale limits leverage
Key Metrics to Watch
- Gross margin expansion - critical to achieving profitability; target 25%+ for pharma sector
- Operating income trajectory - must turn positive to validate business model sustainability
- Operating cash flow sustainability - ensure it remains positive as losses continue
- Cash burn rate and runway - monitor if current reserves of $5.3M remains adequate
- Revenue per dollar of assets - currently low efficiency; assess if scaled operations improve returns
- Gross margin trajectory
- Operating income (and operating margin)
Integrated Biopharma Inc. (INBP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.03x current ratio provides a solid financial cushion.
INBP Profit Margin, ROE & Profitability Analysis
INBP vs Healthcare Sector: How Integrated Biopharma Inc. Compares
How Integrated Biopharma Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Integrated Biopharma Inc. Stock Overvalued? INBP Valuation Analysis 2026
Based on fundamental analysis, Integrated Biopharma Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Integrated Biopharma Inc. Balance Sheet: INBP Debt, Cash & Liquidity
INBP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Integrated Biopharma Inc.'s revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $0.00 indicates the company is currently unprofitable.
INBP Revenue Growth, EPS Growth & YoY Performance
INBP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $11.3M | $116.0K | $0.01 |
| Q1 2026 | $12.7M | $123.0K | $0.00 |
| Q3 2025 | $13.1M | -$59.0K | $-0.01 |
| Q2 2025 | $11.5M | -$59.0K | $0.00 |
| Q1 2025 | $12.9M | -$59.0K | $0.00 |
| Q3 2024 | $13.1M | $16.0K | $0.00 |
| Q2 2024 | $11.5M | -$35.0K | N/A |
| Q1 2024 | $12.3M | -$35.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Integrated Biopharma Inc. Dividends, Buybacks & Capital Allocation
INBP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Integrated Biopharma Inc. (CIK: 0001016504)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INBP
What is the AI rating for INBP?
Integrated Biopharma Inc. (INBP) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INBP's key strengths?
Claude: Zero long-term debt and no leverage provides financial flexibility. Exceptional liquidity with 5.03x current ratio and 2.67x quick ratio enables short-term survival. ChatGPT: Debt-free balance sheet with strong liquidity (current ratio 5.03x; $5.31M cash). Positive operating and free cash flow with low capex needs.
What are the risks of investing in INBP?
Claude: Gross margin of 4.4% is critically low for pharmaceutical industry indicating structural profitability issues. Operating losses of $751K on $24M revenue with negative operating margin of -3.1% show unsustainable business model. ChatGPT: Very thin 4.4% gross margin constrains profitability and resilience. Negative operating income and ROE/ROA signal weak core earnings.
What is INBP's revenue and growth?
Integrated Biopharma Inc. reported revenue of $24.0M.
Does INBP pay dividends?
Integrated Biopharma Inc. does not currently pay dividends.
Where can I find INBP SEC filings?
Official SEC filings for Integrated Biopharma Inc. (CIK: 0001016504) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INBP's EPS?
Integrated Biopharma Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INBP a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Integrated Biopharma Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is INBP stock overvalued or undervalued?
Valuation metrics for INBP: ROE of -3.2% (sector avg: 15%), net margin of -2.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INBP stock in 2026?
Our dual AI analysis gives Integrated Biopharma Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INBP's free cash flow?
Integrated Biopharma Inc.'s operating cash flow is $1.9M, with capital expenditures of $197.0K. FCF margin is 7.2%.
How does INBP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2.7% (avg: 12%), ROE -3.2% (avg: 15%), current ratio 5.03 (avg: 2).